Barclays analyst Peter Lawson lowered the firm’s price target on Arcus Biosciences (RCUS) to $14 from $29 and keeps an Overweight rating on the shares. The firm “derisked” the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS: